AKAO 2017 Annual Report

37 facility. Our current plans anticipate FDA approval of plazomicin in June 2018 and subsequent commercial launch in the United States in 2018, if our NDA is approved by the PDUFA date. C-Scape C-Scape is a combination of ceftibuten, an approved third generation cephalosporin, and clavulanate, an approved -lactamase inhibitor. We purchase clavulanate and ceftibuten from two separate third-party suppliers (or contract manufacturers) who have experience working with these compounds. The clinical drug product (“DP”) for C-Scape is being supplied by a third-party contract manufacturing organization who has experience with these types of compounds. Research and Development Expenses We devote a substantial portion of our resources to developing new product candidates. Please see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Financial Overview and Results of Operations-Research and Development Expenses” for the amounts spent on company-sponsored research and development for the past three fiscal years. Customer Concentration and Geographic Information For the years ended December 31, 2017, 2016 and 2015, all of our revenue has been generated from funding pursuant to U.S. government contracts and a non-profit foundation grant. All contracts receivable relate to funding from the U.S. government. See Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information. All of our revenues for the years ended December 31, 2017, 2016, and 2015 were earned in the United States. All of our long-lived assets are located in the United States. Employees As of February 23, 2018, we had 230 full-time employees. None of our employees is represented by a labor union and we consider our employee relations to be good. Additional Information We view our operations and measure our business as one reportable segment operating primarily in the United States. See Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information. Additional information required by this item is incorporated herein by reference to Part II, Item 6, “Selected Financial Data.” We were incorporated in Delaware in June 2002 and commenced operations in 2004. We completed our initial public offering of our common stock in March 2014. Our mailing address and executive offices are located at 1 Tower Place, Suite 300, South San Francisco, CA 94080 and our telephone number at that address is (650) 800- 3636. We maintain an Internet website at the following address: www.achaogen.com . The information on our website is not incorporated by reference in this annual report on Form 10-K or in any other filings we make with the SEC. We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Exchange Act. These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC.